BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.
The Scientist
Most Recent
Two former Geron CEOs make a bid for the company’s defunct human embryonic stem cell business.
Geron is terminating a clinical trial testing a human embryonic stem cell treatment for spinal cord injury.
Page 1 of 1
Follow The Scientist
Advertisement
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
